2015
Incremental direct and indirect costs of untreated vasomotor symptoms
Sarrel P, Portman D, Lefebvre P, Lafeuille MH, Grittner AM, Fortier J, Gravel J, Duh MS, Aupperle PM. Incremental direct and indirect costs of untreated vasomotor symptoms. Menopause The Journal Of The North American Menopause Society 2015, 22: 260-266. PMID: 25714236, DOI: 10.1097/gme.0000000000000320.Peer-Reviewed Original ResearchConceptsHealthcare resource utilizationVasomotor symptomsOutpatient visitsIndirect costsHigher healthcare resource utilizationRetrospective matched-cohort studyIncremental indirect costsMatched-cohort studySevere vasomotor symptomsCause outpatient visitsHealth insurance claimsControl womenControl cohortLoss daysMost womenWork lossPropensity scoreWomenDirect costsVisitsCost burdenPatientsCohortSymptomsProductivity loss
2005
Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST)
Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal Of Obstetrics And Gynecology 2005, 192: 387-393. PMID: 15695976, DOI: 10.1016/j.ajog.2004.08.017.Peer-Reviewed Original ResearchConceptsMini-Mental State ExaminationEstrogen therapyCognitive declineNormal Mini-Mental State ExaminationDouble-blind trialSecondary stroke preventionTransient ischemic attackIschemic attackPostmenopausal womenStroke preventionRecent strokeStroke trialsCerebrovascular diseaseWomen's EstrogenEstradiol-17betaState ExaminationCognitive measuresEstrogenWomenNormal functionDomain measuresLess declineTherapyStrokeRisk